First Wave BioPharma Chairman and CEO Issues Letter to Stockholders

3 years ago

BOCA RATON, Fla., Feb. 13, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”),…

HOOKIPA Achieves $10 Million Milestone Payment in Development of Immunotherapy for KRAS-Mutated Cancers

3 years ago

NEW YORK and VIENNA, Austria, Feb. 13, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing…

Zentalis Pharmaceuticals Appoints Dr. Iris Roth as Chief Operating Officer

3 years ago

NEW YORK and SAN DIEGO, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Zentalis™ Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused…

Tonix Pharmaceuticals Announces Exclusive License of Potential Therapeutic or Preventative Fully Human and Murine Anti-SARS-CoV-2 Monoclonal Antibodies

3 years ago

Immunocompromised Individuals, Including Organ Transplant Recipients, Are at Increased Risk of Severe COVID-19 and Poor Clinical Outcomes SARS-CoV-2 has Mutated…

Good Supply Cannabis Brand Launches New Product Lineup

3 years ago

New Party Pack Pre-Rolls, Flower and Hash Now Available Across CanadaTORONTO, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Tilray Brands, Inc.…

Amicus Therapeutics Announces Presentations and Posters at the 19th Annual WORLDSymposium™ 2023

3 years ago

PHILADELPHIA, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced that two oral presentations and 11 posters…

Roivant Sciences Reports Financial Results for the Third Quarter Ended December 31, 2022 and Provides Business Update

3 years ago

$9.2M in net product revenue from VTAMA reported for the quarter ended December 31, 2022, with nearly 100,000 VTAMA prescriptions…

CloudMD Makes Mental Health More Accessible with Launch of Spanish Language TAiCBT in the United States

3 years ago

VANCOUVER, British Columbia, Feb. 13, 2023 (GLOBE NEWSWIRE) -- CloudMD Software & Services Inc. (TSXV: DOC, OTCQX: DOCRF, Frankfurt: 6PH)…

G1 Therapeutics Announces Top Line Results from Pivotal Phase 3 Trial of Trilaciclib in Patients Receiving Triplet Therapy with FOLFOXIRI + Bevacizumab for Metastatic Colorectal Cancer (CRC) (PRESERVE 1)

3 years ago

- PRESERVE 1 Achieved its Co-Primary Endpoints Showing Statistically Significant Reductions in Occurrence of Severe Neutropenia During Induction and Duration…

Opthea Phase 2b Trial Results of OPT-302 in Combination with Lucentis® for wet AMD Published in the Journal Ophthalmology

3 years ago

MELBOURNE, Australia, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies…